186 related articles for article (PubMed ID: 24891015)
1. Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia.
Gardner LA; Klawitter J; Gregory MA; Zaberezhnyy V; Baturin D; Pollyea DA; Takebe N; Christians U; Gore L; DeGregori J; Porter CC
Am J Hematol; 2014 Sep; 89(9):896-903. PubMed ID: 24891015
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
3. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
[TBL] [Abstract][Full Text] [Related]
4. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.
Gregory MA; Phang TL; Neviani P; Alvarez-Calderon F; Eide CA; O'Hare T; Zaberezhnyy V; Williams RT; Druker BJ; Perrotti D; Degregori J
Cancer Cell; 2010 Jul; 18(1):74-87. PubMed ID: 20609354
[TBL] [Abstract][Full Text] [Related]
5. Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
Hochhaus A; Ernst T; Eigendorff E; La Rosée P
Ann Hematol; 2015 Apr; 94 Suppl 2():S133-40. PubMed ID: 25814079
[TBL] [Abstract][Full Text] [Related]
6. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Yeh CH; Abdool A; Bruey JM
Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
Luo FR; Yang Z; Camuso A; Smykla R; McGlinchey K; Fager K; Flefleh C; Castaneda S; Inigo I; Kan D; Wen ML; Kramer R; Blackwood-Chirchir A; Lee FY
Clin Cancer Res; 2006 Dec; 12(23):7180-6. PubMed ID: 17145844
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Xiao X; Liu P; Li D; Xia Z; Wang P; Zhang X; Liu M; Liao L; Jiao B; Ren R
J Hematol Oncol; 2020 Jun; 13(1):80. PubMed ID: 32552902
[TBL] [Abstract][Full Text] [Related]
9. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
10. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
Nguyen TK; Rahmani M; Harada H; Dent P; Grant S
Blood; 2007 May; 109(9):4006-15. PubMed ID: 17218385
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib.
Shah NP
Drugs Today (Barc); 2007 Jan; 43(1):5-12. PubMed ID: 17315048
[TBL] [Abstract][Full Text] [Related]
12. [Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia].
Bjerrum OW; Dufva IH; Stentoft J; Hasselbalch HC
Ugeskr Laeger; 2008 Jan; 170(5):331-3. PubMed ID: 18252160
[TBL] [Abstract][Full Text] [Related]
13. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
[TBL] [Abstract][Full Text] [Related]
14. Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.
Agarwal A; Fleischman AG; Petersen CL; MacKenzie R; Luty S; Loriaux M; Druker BJ; Woltjer RL; Deininger MW
Blood; 2012 Sep; 120(13):2658-68. PubMed ID: 22889761
[TBL] [Abstract][Full Text] [Related]
15. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Keam SJ
BioDrugs; 2008; 22(1):59-69. PubMed ID: 18215092
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
19. Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.
Breccia M; Alimena G
BioDrugs; 2011 Jun; 25(3):147-57. PubMed ID: 21528941
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?
Paydas S
Crit Rev Oncol Hematol; 2014 Feb; 89(2):242-7. PubMed ID: 24210599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]